Varex (VREX) Q3 2026 earnings review
Acquisition Overshadows Diverging Segments and Core Margin Weakness
Varex delivered 4% YoY revenue growth in Q3, but the headline masks a stark divergence: the Industrial segment surged 26% while Medical contracted 6%. Bottom-line results appear artificially strong, with non-GAAP gross margin hitting 36.7% and EPS at $0.31. However, these figures are heavily inflated by a one-time $10 million net gross profit benefit from IEEPA tariff refunds. Stripping this away reveals core gross margins still languishing near 31%. Regardless, standalone fundamental analysis is now secondary: the announced acquisition by Teledyne Technologies has prompted the cancellation of the earnings call and the suspension of all forward guidance, pegging the company's near-term trajectory entirely to deal completion dynamics.
🐂 Bull Case
The Industrial segment is accelerating aggressively, jumping 26% YoY to $76.5M. Cargo and vehicle inspection demand is translating into material, sustained revenue.
The pending acquisition by Teledyne virtually eliminates downside operational risk for investors, shifting the focus purely to regulatory approval and deal closure.
🐻 Bear Case
Medical revenue dropped 6% YoY to $134M, marking its lowest output in over five quarters and breaking the narrative that 'Medical headwinds are past.'
Excluding the $10M one-time tariff net benefit, underlying gross margins remain deeply pressured around 31-32%, well below historical averages.
⚖️ Verdict: ⚪
Neutral. Standalone operations show significant flaws—namely the decaying Medical segment and weak core margins—but the Teledyne acquisition overrides fundamental concerns. The stock will trade on deal probability rather than Q3 operational execution.
Key Themes
The Teledyne Acquisition Pivot
The fundamental story of Varex as a standalone entity effectively ended this quarter. Management canceled the earnings call and suspended all forward guidance in light of the proposed sale to Teledyne Technologies. Consequently, metrics like the slow ramp-up of the India facility and elevated inventory levels ($347.1M) transition from being immediate shareholder risks to integration hurdles for the acquirer.
Medical Segment Reverses Course
In Q1 FY26, CEO Sunny Sanyal confidently stated that 'Medical headwinds are truly behind us.' Q3 data explicitly contradicts this narrative. Medical revenue declined 6% YoY to $134.0M, down sharply from $156.2M just one quarter ago. This deceleration suggests that the highly touted 'growing OEM design-in pipeline' is either failing to convert or is being overwhelmed by base business decay.
The Tariff Margin Illusion
Reported GAAP gross margin expanded from 33.3% to 36.4% YoY. However, this is an accounting illusion. The company recognized $17M in refunds from U.S. Customs for previous IEEPA tariffs, offset by a $7M revenue reduction for customer reimbursements. This $10M net injection directly inflated gross profit. Backing out this one-time macro windfall, core gross margin sits closer to 31.7% ($66.7M core profit on $210.5M revenue), signaling that component inflation and India facility ramp costs are still severely pressuring operations.
Cargo Inspection Driving Industrial Acceleration
The Industrial segment remains the undeniable engine of the company, growing 26% YoY to $76.5M. This nearly matches its all-time high of $76.8M set in Q4 FY25. The previously described 'lumpy, tender-driven' cargo and vehicle inspection business is smoothing out into a consistent high-growth driver, validating the company's aggressive inventory build to support these implementations.
Tariff Recovery Salvages Operating Cash Flow
After burning $16M in Q1 and $2M in Q2, Operating Cash Flow reversed to a positive $21M in Q3. However, investors should note this was predominantly driven by the actual receipt of the $17M in U.S. Customs IEEPA tariff refunds. While beneficial to the balance sheet, this is a non-recurring macro-driven cash event, not an improvement in structural working capital management.
Photon Counting as Long-Term Technology Anchor
While overshadowed by the acquisition, the transition to photon counting detectors remains the core long-term technological driver. Varex's engagement with major CT OEMs and broader medical modality partners (CBCT, breast imaging) positions the underlying assets well for the eventual AI-driven imaging evolution, likely forming a key rationale behind Teledyne's purchase.
Standalone Risk: What if the Deal Fails?
If the Teledyne acquisition encounters regulatory friction, Varex's standalone profile is precarious. The company carries $347.1M in inventory (up $48M from FY25 year-end) and $347.1M in total debt. With the Medical segment contracting and core margins struggling in the low 30s, the operational safety net without Teledyne is thin.
Other KPIs
A strong reversal from negative cash flows in Q1 and Q2, bringing the year-to-date operating cash flow to +$3M. However, the $17M cash refund from U.S. Customs accounted for the vast majority of Q3's cash generation.
Down significantly from $145.0 million at the end of FY25. The reduction is primarily tied to the company's debt redemption and refinancing activities executed earlier in the fiscal year, balanced against recent positive cash generation.
Inventory levels remain highly elevated, essentially flat sequentially from Q2's $346.7M, but up substantially from $299.4M at the end of FY25. Management previously stated goals to draw down inventory, but these efforts have yet to materialize on the balance sheet.
Guidance
Due to the pending acquisition by Teledyne Technologies Incorporated, management has formally suspended all financial guidance.
Key Questions
Medical Segment Deterioration
Medical revenue dropped 6% YoY. Which specific modalities or regions drove this unexpected contraction, and does this reflect lost market share or broader capital equipment delays?
Core Margin Trajectory
Excluding the $10M net benefit from IEEPA tariff refunds, gross margins appear to be sitting near 31%. What are the primary structural drags keeping margins depressed, and what is the timeline for the India facility to shift from a headwind to a tailwind?
Inventory Management under Deal Scrutiny
With inventory remaining elevated at $347M, are there specific operational constraints preventing the promised drawdown, or is this buildup explicitly coordinated with Teledyne's integration planning?